TGTX Stock Recent News
TGTX LATEST HEADLINES
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below.
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below.
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below.
Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.
Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue.
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disorders. DTIL is rated a speculative "Buy" due to its undervaluation, promising pipeline, and strategic partnerships, while TGTX is rated "Hold" due to its full valuation.
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy.
TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include a shorter infusion time, lower malignancy risks, and a more favorable price compared to Ocrevus. TGTX's financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite cash runway.
These watch list stocks have beenholding near buy points while the market has been breaking down. The post S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout appeared first on Investor's Business Daily.